- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04415476
Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)
A Randomized, Open-label,Controlled Phase II b Study to Demonstrate Efficacy and Safety of Sirolimus Chronic Rejection After Lung Transplant
This is a prospective single-center, open-label, randomized, controlled pilot
study in the treatment of chronic rejection (CR), defined as grade 1 and 2
BOS, in adult recipients of a pulmonary allograft (single or double lungs).To assess the efficacy and safety of sirolimus plus tacrolimus and prednisone
(S) compared to standard therapy (tacrolimus, mycophenolate mofetil
(MMF) and prednisone) (ST) for chronic rejection, defined as grades 1 and 2
bronchiolitis obliterans syndrome (BOS); BOS defined as ≥ 20% decline
from maximal post-transplant FEV1.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective single-center, open-label, randomized, controlled pilot
study in the treatment of chronic rejection (CR), defined as grade 1 and 2
BOS, in adult recipients of a pulmonary allograft (single or double lungs).
Patients meeting entry criteria shall demonstrate a sustained decline in FEV1
having met stage 1 or 2 BOS. Patients randomized to the study arm, will be
treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus
and prednisone compared to those patients randomized to defined ST alone
(tacrolimus, MMF and prednisone). The trial duration will be approximately
Primary endpoints will include:
Efficacy failure between ST and S randomized group investigational treatment regimens will be determined at 96 weeks after the last patient is randomization and enrolled at approximately study year 2. The control arm will receive standard of care treatment (ST) and immunosuppression according to the University of Maryland lung transplant protocol. Efficacy failure will be defined as the combined end point of progression of BOS (defined as at least a 20 % decline from the initial randomization FEV1 value confirmed by two separate measurements three weeks apart or more) or re-transplantation or death. The co-primary end point of FEV1 and FVC changes to define functional stabilization in the S arm compared to ST is to be completed when the last patient randomized (patient #30) has been enrolled for 2 years as well.
Efficacy of S is to be assessed using following parameters to determine its effect on lung function:
- Forced expiratory volume in one second (FEV1)
- Forced vital capacity (FVC)
- FEF 25-75
Secondary endpoints will include:
- General S tolerability
- Incidence and severity of adverse events (AE)
- Changes in clinical laboratory parameters from baseline after randomization
- Changes in vital signs
- Changes in physical examinations
- Incidence of infections
- Average maintenance doses of calcineurin inhibitors, antimetabolite agents, and corticosteroids
- Number of courses of augmented immunosuppressants
- Number and days of hospitalization
- Incidence of malignancies
- Overall mortality (including transplant-related mortality)
- Retransplantation
Study Type
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Aldo T Iacono, MD
- Phone Number: 410-328-2864
- Email: aiacono@umm.edu
Study Contact Backup
- Name: Cindi T Young, EMT
- Phone Number: 410-328-2451
- Email: cyoung2@som.umaryland.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age: 18 or older.
- Recipient of a single or double pulmonary allograft at least twelve months before study entry.
- Clinically diagnosed BOS grade 1 or 2
- Receiving oral TAC-based immunosuppression according to institutional standards.
- Capable of understanding the purposes and risks of the study, has given written informed consent and agrees to comply with the study requirements and capable of protocol adherence.
- Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to study entry.
- Stable to enable routine pre and post-transplant bronchoscopy with BAL and biopsy.
- Fasting cholesterol < 250 mg/dL, fasting triglycerides < 250 mg/dL -
Exclusion Criteria:
- Active bacterial, viral or fungal infection not successfully resolved at least 4 weeks prior to study entry.
- Mechanical ventilation.
- At screening FEV1 < 1 liter and/or < FEV1 of 25 % predicted.
- Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy.
- Women who breastfeed.
- Known hypersensitivity to sirolimus.
- Serum creatinine value of > 2.5 mg/dL or chronic dialysis use or liver disease with a bilirubin > 2 mg/dL.
- Subjects with severe underlying disease other than BOS that is thought to become fatal within four months of clinical assessment.
- Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to study entry. This is defined as any treatment that is implemented under an Investigational New Drug.
- Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures.
- Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.
- Clinically significant bronchial strictures unresponsive to dilatation procedures.
- Subjects with malignancy diagnosed within one year prior to screen (with the exception of skin cancers).
Lipid panel fasting cholesterol > 250 mg/dL, fasting triglycerides >250 mg/dL
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Sirolimus and Tacrolimus and prednisone
Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)
|
This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs).
Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS.
Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone).
The trial duration will be approximately 2 years for each subject randomized.
Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group.
T
Other Names:
|
Experimental: Standard of Care
Arm1:) sirolimus and tacrolimus and prednisone group: Tacrolimus, The patient will receive 0.1-0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 5-12 ng/ml. Mycophenolate mofetil (NA )Stopped upon sirolimus initiation Sirolimus:1-5 mg/day PO if >40 kg / 1 mg/m²/day if <40 kg trough blood levels 5-12 ng/ml Prednisone:20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effects. Arm 2) Standard Therapy Tacrolimus:0.1 to 0.15 mg/kg/day PO in 2 divided doses Adjust trough blood 8-12 ng/ml Mycophenolate mofetil:750-1250 mg bid PO and adjust to tolerance (WBCs and GI side effects Sirolimus: NA Prednisone: Prednisone dose 20 mg/day PO if >40 kg and 10 mg/day if <40 kg, adjust based on adverse effect |
This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs).
Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS.
Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone).
The trial duration will be approximately 2 years for each subject randomized.
Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group.
T
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death
Time Frame: 2 years
|
Increase in motility
|
2 years
|
Re-Transplantation
Time Frame: 2 years
|
Increase in re-transplantation from baseline
|
2 years
|
FEV1 (Forced Respiratory Volume in 1 second)
Time Frame: 2 years
|
Greater or equal to 20% decline in FEV1 from randomization
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FVC (Forced Vital Capacity)
Time Frame: 2 years
|
Caparison between the two treatment groups.
|
2 years
|
FEF (forced expiratory flow)
Time Frame: 2 years
|
The rate of airflow recorded in measurements of forced vital capacity, usually calculated as an average flow over a given portion of the expiratory curve; the portion between 25 and 75 per cent of forced vital capacity. Comparison on FEF(25-75) between the two treatment groups. |
2 years
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Prednisone
- Tacrolimus
- Mycophenolic Acid
- Sirolimus
Other Study ID Numbers
- HP-00091412
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rejection of Lung Transplant
-
University of ZurichRecruitingChronic Rejection of Lung TransplantSwitzerland
-
University of VirginiaNational Institutes of Health (NIH)RecruitingChronic Rejection of Lung TransplantUnited States
-
Wake Forest University Health SciencesStanford UniversityCompletedRenal Transplant | Rejection Acute Renal | Rejection Chronic Renal | Rejection of Renal Transplant | Renin-Angiotensin SystemUnited States
-
Zambon SpAActive, not recruitingBronchiolitis Obliterans | Lung Transplant Rejection | Lung Transplant; Complications | Lung Transplant Failure and Rejection | Chronic Rejection of Lung Transplant | Chronic Lung Allograft DysfunctionFrance, United States, Spain, Israel, Belgium, Denmark, Germany, United Kingdom, Austria
-
Rabin Medical CenterCompletedChronic Rejection of Cardiac TransplantIsrael
-
Zambon SpAActive, not recruitingBronchiolitis Obliterans | Lung Transplant Rejection | Lung Transplant; Complications | Lung Transplant Failure and Rejection | Chronic Rejection of Lung Transplant | Chronic Lung Allograft DysfunctionFrance, United States, Spain, Israel, Belgium, United Kingdom, Germany
-
Nanjing Medical UniversityUniversity of MinnesotaUnknownChronic Rejection of Liver TransplantChina
-
Stanford UniversityKaiser Foundation Research InstituteCompletedLung Transplant Rejection | Cardiac Transplant RejectionUnited States
-
Hopital FochRecruitingLung Transplant Rejection | Lung Transplant Failure | Lung Transplant; Complications | Lung Transplant Failure and RejectionFrance
-
Lund University HospitalRecruitingLung Transplant Rejection | Chronic Rejection of Lung Transplant | Primary Graft DysfunctionSweden
Clinical Trials on Assigned Interventions
-
Universiti Putra MalaysiaRecruiting
-
Dokuz Eylul UniversityCompletedSmoking Cessation | COPD | Home Visit
-
Sehitkamil Devlet HastanesiCompletedOrthopedic Surgery | Pressure InjuryTurkey
-
Pamukkale UniversityNot yet recruitingBipolar Disorder | Motivational InterviewsTurkey
-
Colorado State UniversityCompleted
-
Eastern Mediterranean UniversityCompletedTreatment | EvaluationCyprus
-
Sinop UniversityRecruiting
-
University of PennsylvaniaChildren's Hospital of PhiladelphiaRecruitingHealth, Subjective | Health Behavior | Environmental Exposure | Financial Stress | Mental Health Wellness | Economic ProblemsUnited States
-
Advanced Medical Solutions Ltd.Cliniscience Sp.Completed
-
Ankara Yildirim Beyazıt UniversityCompletedQuality of Life | Overactive BladderTurkey